Our study supports the need for further research on a broad range of apolipoproteins in CAVD pathobiology and a need to assess whether targeted lowering of specific apolipoproteins, including in ongoing clinical apoC-III-trials not being investigated for CAVD also provide therapeutic CAVD benefits. This evidence concerns the gene APOC3 and congenital bilateral aplasia of vas deferens from CFTR mutation.